Corvus Pharmaceuticals, Inc.
CRVS
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.2B
$14.39
▼ -1.77%
P/E
-22.48
Mkt Cap
$1.2B
52-Wk Range
$5.64–$26.95
52-Week Range
$5.64 - $26.95
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 143.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel immunotherapy mechanisms targeting underexploited pathways (CD73, ITK, A2A receptors)
- Diversified clinical pipeline reducing development risk across multiple cancer indications
- Strategic partnership with Angel Pharmaceuticals enhancing R&D capabilities and resources
- Focused expertise in immuno-oncology with experienced management team in cancer therapeutics
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Emerging player in Biotechnology
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+29.1% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying CRVS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 6, 2026
Reported EPS of -$0.19 vs -$0.16 consensus (-19.4% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-19.4%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CRVS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related